The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/1000 - 1/2000.
1/30 - 1/50.
This is the major myelin protein from the central nervous system. It plays an important role in the formation or maintenance of the multilamellar structure of myelin.
Involvement in disease
Defects in PLP1 are the cause of leukodystrophy hypomyelinating type 1 (HLD1) [MIM:312080]; also known as Pelizaeus-Merzbacher disease. HLD1 is an X-linked recessive dysmyelinating disorder of the central nervous system in which myelin is not formed properly. It is characterized clinically by nystagmus, spastic quadriplegia, ataxia, and developmental delay. Defects in PLP1 are the cause of spastic paraplegia X-linked type 2 (SPG2) [MIM:312920]. SPG2 is characterized by spastic gait and hyperreflexia. In some patients, complicating features include nystagmus, dysarthria, sensory disturbance, mental retardation, optic atrophy.
Immunohistochemical analysis of paraffin-embedded Human brain tissue labeling Myelin PLP with ab183493 at 1/2000 dilution, followed by prediluted HRP Polymer for Rabbit IgG. Counter stained with Hematoxylin.
Immunohistochemical analysis of paraffin-embedded Mouse brain tissue labeling Myelin PLP with ab183493 at 1/2000 dilution, followed by prediluted HRP Polymer for Rabbit IgG. Counter stained with Hematoxylin.